NEWARK, Del, April 04, 2024 (GLOBE NEWSWIRE) -- According to the recently proposed market analysis by Future Market Insights of the ibuprofen API, the global demand for ibuprofen APIs in 2024 is estimated at around US$ 665 million. It is projected to register a CAGR of 2.5% and reach US$ 851 million by 2034. The evolving scenario in emerging economies, the increase in pharmaceutical and biopharmaceutical production, and the growing senior population primarily compel the market growth in the API sector.
Ibuprofen, a non-steroidal anti-inflammatory drug, is used to treat menstrual discomfort, particularly dysmenorrhea, which affects around 1.8 billion people globally. Its APIs, made from active pharmaceutical ingredients like analgesics, antipyretics, and anti-inflammatories, reduce pain, fever, and inflammation. These drugs are often used to relieve menstruation discomfort by blocking prostaglandin.
Get Exclusive Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-11260
The demand for ibuprofen APIs is increasing due to the mound of chronic diseases in developing countries. Pharmaceutical and biochemical organizations are investing in research and development of this medication, which is available in tablets, capsules, and syrups. Elderly patients use the drug to relieve pain, reduce fever, and decrease inflammation. Biopharmaceutical companies are innovating ibuprofen API supplements to treat illnesses like upset stomach, gastrointestinal bleeding, and kidney damage. Various synthetic routes to ibuprofen are being developed to boost market growth and present an optimistic view of the Ibuprofen raw material market.
The synthesis of ibuprofen API faces environmental challenges due to revised production guidelines, impacting manufacturers' costs and raw material sourcing. This has led to a market downturn, as the drug requires high production value. Key pharma and medical producers are researching environmentally friendly synthetic ibuprofen APIs, with opportunities to increase demand through bioinformatics, high-throughput methods, and combinatorial chemistry. Market players must be cautious and flexible to succeed in the industry.
Key Takeaways from the Ibuprofen API Market Report
- The Ibuprofen API industry in Canada is projected to experience a CAGR of 2.0% through 2034.
- The Germany Ibuprofen API market is estimated to demonstrate a CAGR of 2.7% by 2034.
- The Ibuprofen API industry in Italy is anticipated to see a CAGR of 3.3% from 2024 to 2034.
- Spain’s Ibuprofen API sector is projected to showcase a CAGR of 3.7% through 2034.
- France’s Ibuprofen API market is anticipated to display a CAGR of 3.0% by 2034.
“Chronic illnesses in emerging nations fuel the market expansion in the API industry, helmed by the demand for ibuprofen APIs. Pharmaceutical and biopharmaceutical firms allocate resources toward research and development to treat gastrointestinal bleeding, renal damage, and upset stomach ailments. However, environmental issues resulting from new production requirements have caused a decline in the market. Important pharmaceutical and medical companies are investigating environmentally friendly synthetic ibuprofen APIs, potentially boosting demand via combinatorial chemistry, high-throughput techniques, and bioinformatics. Market participants need to be careful and adaptable to prosper in this environment.” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Request Report Methodology:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-11260
Competitive Landscape of the Ibuprofen API Market
Suppliers of pharmaceutical ingredients are collaborating with CMOs to enhance the availability of raw materials and optimize production procedures, resulting in financial and temporal benefits. Due to aims related to global market expansion, pipeline development, and therapeutics, the pharmaceutical API industry is seeing a spike in mergers and acquisitions. In particular, these tactics boost productivity in product development by lowering expenses and generating economies of scale. To achieve long-term success, they also increase market share and attract new clients, which makes them a vital tactic in the ibuprofen API market.
Recent Development in the Ibuprofen API Market
BioSyent Pharma Inc. shipped the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet for short-term pain relief and fever control in Canada in December 2020.
Key Companies
- BASF SE
- BIOCAUSE Inc.
- IOL Chemicals And Pharmaceuticals Limited
- SI Group, Inc.
- Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd.
- Solara Active Pharma Sciences Limited
- Granules India Limited
Buy this Exclusive Report:
https://www.futuremarketinsights.com/checkout/11260
Key Segments
By End User:
- Contract Manufacturing Organizations
- Pharmaceutical Companies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:
- Oligonucleotide API market: Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 5.60% from 2024 to 2034. As such, the global oligonucleotide API market is projected to increase from a valuation of US$ 2.81 billion in 2024 to US$ 4.84 billion by the end of 2034.
- Small molecule API market: The small molecule API market revenue is expected to reach US$ 174 billion by 2033. A CAGR of 4.1% is expected for the small molecule API market during the forecast period.
- Antibiotics active pharmaceutical ingredient (API) market: The global antibiotics active pharmaceutical ingredient (API) market is expected to reach US$ 12002.3 million by 2033, trailing a CAGR of 3.3% during the forecast period.
- Healthcare API market: The global Healthcare API market is to reach a valuation of US$ 316.2 Million by the year 2033, and is further projected to expand at a CAGR of 3.6% to reach a valuation of US$ 316.2 Million by the year 2033.
- Cancer Tissue Diagnostic Market Demand: The cancer tissue diagnostic market has exhibited an ascending trend, where its value is estimated to go from US$ 15,302.2 million in 2024 to US$ 23,516.2 million in 2034. Adoption of cancer tissue diagnostics is exhibiting a CAGR of 4.5% from 2024 to 2034.
- Therapeutic Nuclear Medicine Market Trends: The therapeutic nuclear medicine market is foreseen to register a CAGR of 4.10% from 2024 to 2034, with a market valuation of US$ 1.32 billion in 2024. Developing demand is invoked to set a valuation of US$ 1.97 billion in 2034 for the market.
- Specialty Active Pharmaceutical Ingredient Market: The demand for specialty active pharmaceutical ingredients is expected to increase at a CAGR of 3.2% over the forecast period. The specialty active pharmaceutical ingredient (API) market value is expected to reach US$ 282.88 billion by 2033.
- Cataract Surgery Device Market Opportunity: The cataract surgery device market has exhibited an ascending trend, where its value is estimated to go from US$ 8,928 million in 2024 to US$ 12,472.70 million in 2034. Adoption of cataract surgery devices is exhibiting a growth rate of 3.40% from 2024 to 2034.
- Live Stock Vaccine Market Outlook: The livestock vaccine market is predicted to be valued at US$ 6.1 billion in 2024 and rise to US$ 11.2 billion by 2034. The market is expected to grow at a CAGR of 6.2% during the forecast period.
- Anti-aging Product Service and Device Market Strategies: As per the FMI’s revised market report, sales of anti-aging product services and devices accumulate a present valuation of US$ 60,764.40 million in 2024. Going by this trend, the anti-aging product service market amplifies and equates to a market worth US$ 1,01,843.40 million, with a steady CAGR of 5.30% by 2034.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blogs | YouTube
